Cargando…

Igf2 ligand dependency of Pten(+/−) developmental and tumour phenotypes in the mouse

The tumour suppressor PTEN is a key negative regulator of the PI3K-Akt pathway, and is frequently either reduced or lost in human tumours. Murine genetic studies have confirmed that reduction of Pten promotes tumourigenesis in multiple organs, and demonstrated dependency of tumour development on the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Church, D N, Phillips, B R, Stuckey, D J, Barnes, D J, Buffa, F M, Manek, S, Clarke, K, Harris, A L, Carter, E J, Hassan, A B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419984/ https://www.ncbi.nlm.nih.gov/pubmed/22120709 http://dx.doi.org/10.1038/onc.2011.526

Ejemplares similares

Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes
por: Haley, Victoria L, et al.
Publicado: (2012)

Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN.
por: Gray, I. C., et al.
Publicado: (1998)

Maternal Transmission of a Humanised Igf2r Allele Results in an Igf2 Dependent Hypomorphic and Non-Viable Growth Phenotype
por: Hughes, Jennifer, et al.
Publicado: (2013)

Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas
por: Freihoff, D, et al.
Publicado: (1999)

The expression profile for the tumour suppressor gene PTEN and associated polymorphic markers
por: Hamilton, J A, et al.
Publicado: (2000)

Differential expression of PTEN gene correlates with phenotypic heterogeneity in three cases of patients showing clinical manifestations of PTEN hamartoma tumour syndrome
por: Paparo, Lorella, et al.
Publicado: (2013)

PTEN Protein Phosphatase Activity Is Not Required for Tumour Suppression in the Mouse Prostate
por: Wise, Helen M., et al.
Publicado: (2022)

A novel germline mutation of PTEN associated with brain tumours of multiple lineages
por: Staal, F J T, et al.
Publicado: (2002)

Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
por: Gallardo, A, et al.
Publicado: (2012)

Detection and Yield of Colorectal Cancer Surveillance in Adults with PTEN Hamartoma Tumour Syndrome
por: Drissen, Meggie M. C. M., et al.
Publicado: (2022)

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
por: Punnoose, Elizabeth A, et al.
Publicado: (2015)

NLK Is a Novel Therapeutic Target for PTEN Deficient Tumour Cells
por: Mendes-Pereira, Ana M., et al.
Publicado: (2012)

Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis
por: Jubb, Adrian M, et al.
Publicado: (2010)

ATM Kinase Inhibition Preferentially Sensitises PTEN-Deficient Prostate Tumour Cells to Ionising Radiation
por: Hanna, Conor, et al.
Publicado: (2020)

Characterizing Variants of Unknown Significance of the PTEN tumour suppressorHomolog DAF-18
por: Ermakova, Glafira, et al.
Publicado: (2022)

Intermittent fasting uncovers and rescues cognitive phenotypes in PTEN neuronal haploinsufficient mice
por: Cabral-Costa, J. V., et al.
Publicado: (2018)

Honey Bee PTEN – Description, Developmental Knockdown, and Tissue-Specific Expression of Splice-Variants Correlated with Alternative Social Phenotypes
por: Mutti, Navdeep S., et al.
Publicado: (2011)

Tumours and tremors: how PTEN regulation underlies both
por: Kim, R H, et al.
Publicado: (2006)

Overexpressing TPTE2 (TPIP), a homolog of the human tumor suppressor gene PTEN, rescues the abnormal phenotype of the PTEN(−/−) mutant
por: Lusche, Daniel F., et al.
Publicado: (2018)

Production of immunoreactive insulin-like growth factor-I (IGF-I) and IGF-I binding proteins by human lung tumours.
por: Reeve, J. G., et al.
Publicado: (1990)

Investigation of Igf-1, Igf-Bp3 and Igf-Bp5 levels in umbilical cord blood of infants with developmental dysplasia of the hip
por: DEMİREL, Esra, et al.
Publicado: (2023)

Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes
por: Spinelli, Laura, et al.
Publicado: (2015)

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours
por: Wilky, B A, et al.
Publicado: (2015)

Early-onset renal cell carcinoma in PTEN harmatoma tumour syndrome
por: Kim, Raymond H., et al.
Publicado: (2020)

Characteristics of PTEN Mutation in Thyroid Tumours: A Retrospective Chart Review
por: Bandargal, Saruchi, et al.
Publicado: (2023)

Wnt ligands influence tumour initiation by controlling the number of intestinal stem cells
por: Huels, D. J., et al.
Publicado: (2018)

Distinguishing between PTEN clinical phenotypes through mutation analysis
por: Portelli, Stephanie, et al.
Publicado: (2021)

Association analysis of the IGF1 gene with childhood growth, IGF-1 concentrations and type 1 diabetes
por: Vella, A., et al.
Publicado: (2008)

Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours
por: Trojan, Jerzy, et al.
Publicado: (2012)

Effects of indomethacin on expression of PTEN tumour suppressor in human cancers
por: Abdulkareem, Imran Haruna, et al.
Publicado: (2013)

Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome
por: Tischkowitz, Marc, et al.
Publicado: (2020)

Emerging role of PTEN loss in evasion of the immune response to tumours
por: Vidotto, Thiago, et al.
Publicado: (2020)

The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer
por: Turnham, Daniel J., et al.
Publicado: (2020)

IGF signalling in germ cells and testicular germ cell tumours: roles and therapeutic approaches
por: Selfe, J., et al.
Publicado: (2019)

Erratum to “Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours”
por: Trojan, Jerzy, et al.
Publicado: (2012)

Superoxide anion radicals induce IGF-1 resistance through concomitant activation of PTP1B and PTEN
por: Singh, Karmveer, et al.
Publicado: (2015)

Various phenotypes of short stature with heterozygous IGF-1 receptor (IGF1R) mutations
por: Kawashima-Sonoyama, Yuki, et al.
Publicado: (2022)

Catalysis by the Tumor-Suppressor Enzymes PTEN and PTEN-L
por: Johnston, Sean B., et al.
Publicado: (2015)

Impaired Pten Expression in Human Malignant Peripheral Nerve Sheath Tumours
por: Bradtmöller, Maren, et al.
Publicado: (2012)

Tumour suppressor PTEN activity is differentially inducible by myo‐inositol phosphates
por: Grzymajlo, Krzysztof, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4kdghoiflv3mg1rltcn0qkell2